Stemline Therapeutics, Inc. (STML) Given “Buy” Rating at HC Wainwright
“Bio-Path reported 1Q17 with operating expenses of $2M which were offset by a change in non-cash warrant liability for a net loss of $0.4M. Bio-Path ended the period with $7.1M in cash, sufficient runway to the end of the year.”,” the firm’s analyst commented.
Other equities analysts have also issued reports about the stock. Cowen and Company restated a buy rating on shares of Stemline Therapeutics in a research report on Thursday, February 2nd. Jefferies Group LLC set a $16.00 price target on shares of Stemline Therapeutics and gave the company a buy rating in a research report on Friday, February 3rd. Ladenburg Thalmann Financial Services reaffirmed a buy rating on shares of Stemline Therapeutics in a research note on Monday, February 6th. Zacks Investment Research raised shares of Stemline Therapeutics from a sell rating to a hold rating in a research note on Thursday, February 9th. Finally, Wedbush boosted their target price on shares of Stemline Therapeutics from $33.00 to $40.00 and gave the stock an outperform rating in a research note on Thursday, May 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $29.17.
Shares of Stemline Therapeutics (NASDAQ:STML) traded up 7.79% during midday trading on Monday, hitting $8.30. 691,218 shares of the company’s stock traded hands. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $14.60. The company has a 50 day moving average price of $8.08 and a 200 day moving average price of $9.28. The firm’s market capitalization is $194.02 million.
Stemline Therapeutics (NASDAQ:STML) last released its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by $0.22. The firm had revenue of $0.30 million during the quarter, compared to analyst estimates of $0.30 million. Stemline Therapeutics had a negative net margin of 3,864.20% and a negative return on equity of 60.51%. Equities analysts anticipate that Stemline Therapeutics will post ($2.27) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/06/16/stemline-therapeutics-inc-stml-rating-reiterated-by-hc-wainwright-updated-updated-updated.html.
Large investors have recently bought and sold shares of the company. Nationwide Fund Advisors increased its stake in Stemline Therapeutics by 7.8% in the first quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 858 shares during the period. Perceptive Advisors LLC acquired a new stake in Stemline Therapeutics during the fourth quarter worth $115,000. Wells Fargo & Company MN increased its stake in Stemline Therapeutics by 3.8% in the first quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 500 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Stemline Therapeutics during the first quarter worth $120,000. Finally, Ladenburg Thalmann Financial Services Inc. increased its stake in Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 11,300 shares during the period. 54.72% of the stock is owned by institutional investors and hedge funds.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Stock Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related stocks with our FREE daily email newsletter.